Autonomic

Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

Retrieved on: 
Wednesday, December 13, 2023
Research, Neurology, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Medicine, Safety, Pain, Aes, Vertex, Pain management, Patient, TID, Week, Diabetic neuropathy, Medical Affairs Bureau, Autonomic, VRTX, DPN, Șaeș, Neuropathic pain, Vertex Pharmaceuticals, Pharmaceutical industry, Birth control

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN).

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN).
  • The study also included an active reference arm of pregabalin to support the evaluation of the VX-548 treatment effect.
  • VX-548 was generally well tolerated at all doses tested in the study.
  • Most adverse events (AEs) were mild to moderate and there were no serious adverse events (SAEs) related to VX-548.

Cloud Computing Market worth $1,266.4 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, December 7, 2023
Online, Berkshire Hathaway, Adobe, Final good, Disaster, Acquisition, Facial recognition, Internet of things, Shapeways, Organization, Software, Salesforce, Infrastructure as a service, MNM, IBM, Ocado, Cloud computing, CRM, Platform as a service, SME, Intelligence, Autonomic, Machine learning, Automation, Temple of Azure Clouds, IBM Consulting, Geographic Locator Codes, Partnership, Software as a service, Communication, Growth, ERP, AI, Microsoft, Walmart, Google Cloud, Alibaba Cloud, Video game, Mobile phone, Bank, Cloud, Service

The Cloud Computing Market is expanding, and vendors are adopting a strategic focus to attract customers.

Key Points: 
  • The Cloud Computing Market is expanding, and vendors are adopting a strategic focus to attract customers.
  • These services are increasing the demand for the Cloud Computing Market.
  • In recent years, cloud computing has emerged as a game-changing technology that significantly benefits the industry.
  • North America is estimated to account for the largest market share in the global Cloud Computing Market in 2023, and this trend will continue during the forecast period.

Cloud Computing Market worth $1,266.4 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, December 7, 2023
Online, Berkshire Hathaway, Adobe, Final good, Disaster, Acquisition, Facial recognition, Internet of things, Shapeways, Organization, Software, Salesforce, Infrastructure as a service, MNM, IBM, Ocado, Cloud computing, CRM, Platform as a service, SME, Intelligence, Autonomic, Machine learning, Automation, Temple of Azure Clouds, IBM Consulting, Geographic Locator Codes, Partnership, Software as a service, Communication, Growth, ERP, AI, Microsoft, Walmart, Google Cloud, Alibaba Cloud, Video game, Mobile phone, Bank, Cloud, Service

The Cloud Computing Market is expanding, and vendors are adopting a strategic focus to attract customers.

Key Points: 
  • The Cloud Computing Market is expanding, and vendors are adopting a strategic focus to attract customers.
  • These services are increasing the demand for the Cloud Computing Market.
  • In recent years, cloud computing has emerged as a game-changing technology that significantly benefits the industry.
  • North America is estimated to account for the largest market share in the global Cloud Computing Market in 2023, and this trend will continue during the forecast period.

BT and Google Cloud Advance Cybersecurity With New Partnership

Retrieved on: 
Wednesday, October 11, 2023
Cloud, Partnership, Chronicle, Intelligence, Security, Risk management, AI, Google Cloud, Cyberattack, BT Enterprise, ASO, Google Cloud Platform, Public sector, Autonomic, BT Group, Security Advisory Services, BT, Face, BigQuery, Mobile phone, Network equipment provider, Looker

BT announces new strategic security partnership with Google Cloud, targeting a range of joint innovation opportunities.

Key Points: 
  • BT announces new strategic security partnership with Google Cloud, targeting a range of joint innovation opportunities.
  • LONDON and SUNNYVALE, Calif., Oct. 11, 2023 /PRNewswire/ -- BT and Google Cloud today announced a new partnership focusing on an enhanced commitment to cybersecurity innovation.
  • The partnership builds on BT Group and Google's existing relationship to house BT Group's data in Google Cloud to support its analytics and AI ambitions.
  • BT and Google Cloud will also seek to incorporate solutions from Mandiant, a market leader in threat intelligence solutions acquired by Google in 2022, as an additional aspect of the partnership.

URC and the Custom Installation Industry Celebrate the 9th Annual Unsurpassed Awards

Retrieved on: 
Thursday, September 7, 2023
Lighting, Paradigm, Human, HDA, Total, Autonomic, International, Academy Award for Best International Feature Film, Joel Spira (businessman), Sennheiser, Aesthetics, Potter, Samsung, CIS, Automation, Element, History, Creativity, Via, HVAC, URC, Total Control, Apple, LG, System, Sensation, Mobile phone, Auction, Tenterden, CEDIA

HARRISON,N.Y., Sept. 7, 2023 /PRNewswire-PRWeb/ -- URC, a global leader in smart home automation and control for residential and commercial applications, announced today, from CEDIA, the winners of its 9th annual Unsurpassed Awards.

Key Points: 
  • HARRISON,N.Y., Sept. 7, 2023 /PRNewswire-PRWeb/ -- URC, a global leader in smart home automation and control for residential and commercial applications, announced today, from CEDIA, the winners of its 9th annual Unsurpassed Awards.
  • Mr. Chang K. Park, URC's Founder and CEO
    Launched in 2014, URC's Unsurpassed Awards celebrate excellence and creativity in residential and commercial automation installations.
  • Entries include inspiring environments and large installations with URC's Total Control® controlling hundreds of smart home and commercial devices.
  • Winners of the 2023 URC's Unsurpassed Awards include the following URC dealers:
    Custom Integrated Solutions (Youngstown, OH) http://www.cisohio.com/ A first-time winner takes the top prize for an incredible residential installation.

CND Life Sciences Enters into Licensing and Collaboration Agreement to Advance Diagnostic Technology for Neurodegenerative Diseases

Retrieved on: 
Wednesday, March 22, 2023
CND, Autonomic, Therapy, Beth Israel Deaconess Medical Center, Research, Doctor of Philosophy, Disorder, Dementia, Parkinson's disease, MD, Patient, Frustration, Neuroscience, Alpha-synuclein, Lewy body, Diagnosis, Health, Synucleinopathy, Alzheimer's disease, Skin, Caregiver, Pharmaceutical industry, PHOENIX

PHOENIX and BOSTON, March 22, 2023 /PRNewswire/ -- CND Life Sciences, a medical technology company pioneering the development of highly accurate skin-based tests to help clinicians diagnose neurodegenerative disorders like Parkinson's disease and dementia with Lewy bodies, has entered into a licensing collaboration with Beth Israel Deaconess Medical Center (BIDMC) in Boston to advance CND's scientific platform and patient-focused mission.

Key Points: 
  • Additionally, CND and BIDMC are exploring opportunities to identify other protein markers in the skin that are pathological hallmarks of other neurodegenerative diseases.
  • The lack of diagnostic certainty can lead to unnecessary tests, frustration by patients and caregivers, and suboptimal care.
  • "BIDMC looks forward to working with CND in the field of neurobiology," said Gyongyi Szabo, MD, PhD, Chief Academic Officer of BIDMC.
  • "Technological breakthroughs in neurodegeneration diagnosis and treatment should substantially improve patient care in the next decade."

AUTONOMIC launches Fellowship Program for founders and their teams who have been impacted by the Silicon Valley Bank failure

Retrieved on: 
Tuesday, March 21, 2023
Uncertainty, Silicon, Silicon Valley Bank, Research, SVB, Multimedia, Mobile phone, Cryptocurrency, Online shopping, Autonomic

The fellowship program is designed specifically to support founders and their teams manage stress and optimize overall brain performance during this turbulent time.

Key Points: 
  • The fellowship program is designed specifically to support founders and their teams manage stress and optimize overall brain performance during this turbulent time.
  • "Under the current circumstances with Silicon Valley Bank (SVB) founders need to come together and support one another in the ways we best know how.
  • The fellowship program is open to founders from all industries and backgrounds who have been impacted by the (SVB) failure.
  • For more information about the fellowship program, including eligibility requirements and application details, visit Autonomic's website at www.getautonomic.com/fellowship
    View original content to download multimedia: https://www.prnewswire.com/news-releases/autonomic-launches-fellowship-p...

Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System

Retrieved on: 
Wednesday, November 2, 2022
American Autonomic Society, AAS, Center, Clinical trial, Parkinson's disease, Autonomic nervous system, Biopharma LLC, NASDAQ, Company, Pure autonomic failure, Autonomic, Patient, Multiple system atrophy, Noh, International Symposium on Endovascular Therapy, 2021 Essex County Council election, Drug development, Bachelor of Medicine, Bachelor of Surgery, LS, Quality of life, Beth Israel Deaconess Medical Center, Orthostatic hypotension, MSA, Caregiver burden, Pharmaceutical industry, Hydraulic machinery, Neurology

DUBLIN, Nov. 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc.("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today will present new ampreloxetine data in neurogenic orthostatic hypotension (nOH) from the Company's Phase 3 program at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society (AAS).

Key Points: 
  • DUBLIN, Nov. 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc.("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today will present new ampreloxetine data in neurogenic orthostatic hypotension (nOH) from the Company's Phase 3 program at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society (AAS).
  • Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic nOH in patients with multiple system atrophy (MSA).
  • "These ampreloxetine data are encouraging for patients with MSA suffering with neurogenic orthostatic hypotension.
  • MSA is a progressive brain disorder that affects movement and balance and disrupts the function of the autonomic nervous system.

Mandiant Announces Initial mWISE Conference 2022 Keynote Lineup

Retrieved on: 
Wednesday, August 31, 2022
Data Management, Security, Technology, Software, Internet, Hardware, Cloud, Thomson Reuters, Cybersecurity and Infrastructure Security Agency, Hunton Andrews Kurth, Ford Motor Company, Application, Government, NASDAQ, Cyber threat intelligence, Cyberwarfare, Google Cloud, Colonial Pipeline, Red, Senior, Intelligence, SOC, Computer security, CISA, CrowdStrike, Multimedia, SolarWinds, Organization, Supply chain risk management, Autonomic, Risk management, Conference, Information security operations center, Target, Knowledge, The New York Times, Industry, Intelligence analysis, Security, Social media, Private sector, Weapon, Mandiant

Mandiant, Inc. (NASDAQ: MNDT) today unveiled new details on mWISE Conference 2022 , which will take place October 18-20 in Washington, D.C., along with a virtual option.

Key Points: 
  • Mandiant, Inc. (NASDAQ: MNDT) today unveiled new details on mWISE Conference 2022 , which will take place October 18-20 in Washington, D.C., along with a virtual option.
  • mWISE Conference 2022 will deliver dynamic mainstage addresses across three action-packed days.
  • In addition to dynamic mainstage presentations, mWISE Conference 2022 will feature more than 70 sessions , both live and on-demand.
  • To learn more about mWISE Conference 2022 and to register for in-person or remote attendance, visit https://mwise.mandiant.com
    Since 2004, Mandiant has been a trusted partner to security-conscious organizations.

Praxis Precision Medicines Announces Publication of Preclinical Data Highlighting Differentiated and Potent Antiepileptic Activity of PRAX-562

Retrieved on: 
Tuesday, January 18, 2022
American Epilepsy Society, Patient, Autonomic, Epilepsy, Seizure, AED, Central nervous system, LinkedIn, Conjunctiva, ASSR, Private Securities Litigation Reform Act, European Medicines Agency, CNS, COVID-19, Central nervous system disease, Movement disorders, Adult, NASDAQ, NAV, Gene, GLOBE, Sodium, Review, Calcium channel, Physiology, Trigeminal neuralgia, Development of the human body, U.S. Securities and Exchange Commission, Goal, SUNA, Company, Disorder, Depression, Pathology, Food, Lists of diseases, Twitter, Brain, Security (finance), SUNCT, Food and Drug Administration Amendments Act of 2007, Dees, Judgement, Annual report, Pharmaceutical industry, Praxis

BOSTON, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the publication of data in the journal Epilepsia from a preclinical study of PRAX-562, a preferential persistent sodium channel blocker currently in development for the potential treatment of rare adult cephalgias and Developmental and Epileptic Encephalopathies (DEEs).

Key Points: 
  • This preclinical study investigated the effects of PRAX-562 on intrinsic neuronal excitability and protection from induced seizures as compared to sodium channel blockers used as standard-of-care antiepileptic treatments.
  • In the study, PRAX-562 demonstrated robust preclinical antiseizure activity and significantly improved preclinical tolerability, with improved or comparable efficacy when evaluated against currently used sodium channel blockers.
  • This study supports the potential for PRAX-562, a persistent sodium channel blocker with a favorable therapeutic window, to improve tolerability relative to marketed therapies while achieving potent antiseizure activity.
  • Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.